172 related articles for article (PubMed ID: 37972196)
1. Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly.
Shi X; Lingerak R; Herting CJ; Ge Y; Kim S; Toth P; Wang W; Brown BP; Meiler J; Sossey-Alaoui K; Buck M; Himanen J; Hambardzumyan D; Nikolov DB; Smith AW; Wang B
Science; 2023 Dec; 382(6674):1042-1050. PubMed ID: 37972196
[TBL] [Abstract][Full Text] [Related]
2. EphA2 Receptor Unliganded Dimers Suppress EphA2 Pro-tumorigenic Signaling.
Singh DR; Ahmed F; King C; Gupta N; Salotto M; Pasquale EB; Hristova K
J Biol Chem; 2015 Nov; 290(45):27271-27279. PubMed ID: 26363067
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.
Yang NY; Fernandez C; Richter M; Xiao Z; Valencia F; Tice DA; Pasquale EB
Cell Signal; 2011 Jan; 23(1):201-12. PubMed ID: 20837138
[TBL] [Abstract][Full Text] [Related]
4. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
5. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
Salaita K; Nair PM; Petit RS; Neve RM; Das D; Gray JW; Groves JT
Science; 2010 Mar; 327(5971):1380-5. PubMed ID: 20223987
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.
Koshikawa N; Hoshino D; Taniguchi H; Minegishi T; Tomari T; Nam SO; Aoki M; Sueta T; Nakagawa T; Miyamoto S; Nabeshima K; Weaver AM; Seiki M
Cancer Res; 2015 Aug; 75(16):3327-39. PubMed ID: 26130649
[TBL] [Abstract][Full Text] [Related]
7. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers.
Singh DR; Pasquale EB; Hristova K
Biochim Biophys Acta; 2016 Sep; 1860(9):1922-8. PubMed ID: 27281300
[TBL] [Abstract][Full Text] [Related]
8. Emerging and Diverse Functions of the EphA2 Noncanonical Pathway in Cancer Progression.
Zhou Y; Sakurai H
Biol Pharm Bull; 2017; 40(10):1616-1624. PubMed ID: 28966234
[TBL] [Abstract][Full Text] [Related]
9. PIP
Stefanski KM; Russell CM; Westerfield JM; Lamichhane R; Barrera FN
J Biol Chem; 2021; 296():100149. PubMed ID: 33277361
[TBL] [Abstract][Full Text] [Related]
10. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
11. EphB6 promotes anoikis by modulating EphA2 signaling.
Akada M; Harada K; Negishi M; Katoh H
Cell Signal; 2014 Dec; 26(12):2879-84. PubMed ID: 25239188
[TBL] [Abstract][Full Text] [Related]
12. The SAM domain inhibits EphA2 interactions in the plasma membrane.
Singh DR; Ahmed F; Paul MD; Gedam M; Pasquale EB; Hristova K
Biochim Biophys Acta Mol Cell Res; 2017 Jan; 1864(1):31-38. PubMed ID: 27776928
[TBL] [Abstract][Full Text] [Related]
13. An ephrin mimetic peptide that selectively targets the EphA2 receptor.
Koolpe M; Dail M; Pasquale EB
J Biol Chem; 2002 Dec; 277(49):46974-9. PubMed ID: 12351647
[TBL] [Abstract][Full Text] [Related]
14. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
[TBL] [Abstract][Full Text] [Related]
15. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.
Miao H; Li DQ; Mukherjee A; Guo H; Petty A; Cutter J; Basilion JP; Sedor J; Wu J; Danielpour D; Sloan AE; Cohen ML; Wang B
Cancer Cell; 2009 Jul; 16(1):9-20. PubMed ID: 19573808
[TBL] [Abstract][Full Text] [Related]
16. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
Barquilla A; Lamberto I; Noberini R; Heynen-Genel S; Brill LM; Pasquale EB
Mol Biol Cell; 2016 Sep; 27(17):2757-70. PubMed ID: 27385333
[TBL] [Abstract][Full Text] [Related]
18. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade.
Pratt RL; Kinch MS
Oncogene; 2002 Oct; 21(50):7690-9. PubMed ID: 12400011
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.
Annamalai B; Liu X; Gopal U; Isaacs JS
Mol Cancer Res; 2009 Jul; 7(7):1021-32. PubMed ID: 19567782
[TBL] [Abstract][Full Text] [Related]
20. Point mutations in dimerization motifs of the transmembrane domain stabilize active or inactive state of the EphA2 receptor tyrosine kinase.
Sharonov GV; Bocharov EV; Kolosov PM; Astapova MV; Arseniev AS; Feofanov AV
J Biol Chem; 2014 May; 289(21):14955-64. PubMed ID: 24733396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
